| Ytd | -52.56% | |
| 1y | -90.49% |
| Open | 1.93 | Prev Close | 1.95 | Low | 1.91 | High | 2.05 | Mkt Cap | 19.14M |
| Vol | 21.60K | Avg Vol | 161.41K | EPS | -0.27 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-08 | 50-d Avg | 3.12 | 200-d Avg | 7.27 | 1yr Est | 0.00 |
TVRD News
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiati
HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD)
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the anal
https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to U
Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral a
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the an
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the anal
Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers th
Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Over
The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical tr
